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Cancer cells within individual tumors often exist in
distinct phenotypic states that differ in functional
attributes. While cancer cell populations typically
display distinctive equilibria in the proportion of cells
in various states, the mechanisms by which this
occurs are poorly understood. Here, we study the
dynamics of phenotypic proportions in human breast
cancer cell lines. We show that subpopulations of
cells purified for a given phenotypic state return
towards equilibrium proportions over time. These
observations can be explained by a Markov model
in which cells transition stochastically between
states. A prediction of thismodel is that, given certain
conditions, any subpopulation of cells will return
to equilibrium phenotypic proportions over time. A
second prediction is that breast cancer stem-like
cells arise de novo from non-stem-like cells. These
findings contribute to our understanding of cancer
heterogeneity and reveal how stochasticity in
single-cell behaviors promotes phenotypic equilib-
rium in populations of cancer cells.
INTRODUCTION
The regulation of cell-state decisions is critical for the survival of
living systems. In unicellular organisms, cell-state changes occur
in response to environmental stressors or nutrient changes.
Direct sensing of environmental stimuli often involves stochastic
cell-fate decisions, modulated by random noise in gene expres-
sion (Su¨el et al., 2006, 2007). Such probabilistic behavior has
been shown to be advantageous in certain environmental condi-
tions (Kussell and Leibler, 2005; Thattai and van Oudenaarden,2004; Wolf et al., 2005). Noisy gene-expression levels can also
stochastically influence cell-state decisions in eukaryotes
(Di Talia et al., 2007). However, less is known about the role
that stochasticity might play in regulating cell-state equilibria in
populations of cells.
Cell-state dynamics are of particular significance in tumor
pathobiology. Even within individual tumors, cancer cells
frequently exist in any of several possible phenotypic states.
Cancer cells in distinct phenotypic states often exhibit important
differences in functional properties. For example, subpopula-
tions of stem-like cancer cells with increased tumor-seeding
ability and drug resistance have been identified in a variety of
tumor types (Al-Hajj et al., 2003; Lapidot et al., 1994; Li et al.,
2007; Singh et al., 2004; Smalley and Ashworth, 2003; Stingl
and Caldas, 2007). The proportion of cancer cells in the various
states is related to both tumor type and grade (Chiou et al., 2008;
Harris et al., 2008). Additionally, because anticancer therapies
preferentially kill specific cancer cell states, treatment can result
in selective changes in phenotypic proportions within tumors
(Creighton et al., 2009; Gupta et al., 2009; Li et al., 2008; Wood-
ward et al., 2007). Understanding how cancer cell states coexist
and evolve within tumors is of fundamental interest and could
facilitate the development of more effective therapies.
Phenotypic equilibrium in cell-state proportions is observed
in vivo and in cell lines adapted to in vitro culture. Under fixed
conditions, both normal and cancerous epithelial lines display
stable proportions of cells in stem-like, basal, or luminal states
during propagation in culture. The mechanisms that stabilize
phenotypic proportions within cellular populations remain
unclear. Two general classes of mechanisms can be envisioned:
(1) in the absence of interconversion between states, equilibrium
proportions could be maintained through intercellular signals
that modulate the proliferation rates of distinct states and (2)
proliferation rates remain equal, but cancer cells could intercon-
vert between different states in a manner that maintains equilib-
rium cell-state proportions.Cell 146, 633–644, August 19, 2011 ª2011 Elsevier Inc. 633
Here, we study the mechanisms that underlie phenotypic
diversity in populations of cancer cells. We develop and validate
a quantitative Markov model of phenotypic transitions that
predicts evolution toward equilibrium proportions in cancer cell
populations. The Markov model makes several unanticipated
predictions about cell-state transitions and dynamics in cancer
cell populations. In addition, the proposed model is useful in
characterizing the effects of genetic and chemical perturbations
on phenotypic proportions in cancer cell populations.
RESULTS
Characterization of Luminal, Basal, and Stem-like
Differentiation States in Breast Cancer Cells
To study cell-state dynamics in cancer cells, we used fluores-
cence-activated cell sorting (FACS) to isolate three mammary
epithelial cell states that have been previously defined and
characterized using cell-surface markers: stem-like (CD44hi
CD24negEpCAMlo), basal (CD44hiCD24negEpCAMneg), and
luminal (CD44loCD24hiEpCAMhi) (Fillmore and Kuperwasser,
2008; Shipitsin et al., 2007). Using this system, we isolated
each of these cellular fractions from two human breast cancer
lines derived from primary tumors (SUM159 and SUM149), re-
sulting in subpopulations that exhibited significant differences
in morphology in culture (Figures 1A and 1B). To confirm that
these markers indeed define cells in the expected cell-differenti-
ation states, we collected global gene expression data from
sorted CD44hiCD24negEpCAMlo (stem-like), CD44hiCD24neg
EpCAMneg (basal), or CD44loCD24hiEpCAMhi (luminal) subpopu-
lations of the SUM149 and SUM159 breast cancer lines. We next
applied gene set enrichment analysis (GSEA) (Mootha et al.,
2003;Subramanianet al., 2005) todeterminewhether theexpres-
sion levels of genes previously reported to be associated with
stem, basal, and luminal differentiationwere specifically enriched
in the relevant sorted subpopulations (Assou et al., 2007; Black-
man et al., 2005; Bo¨cker et al., 2002; Brambrink et al., 2008; Bus-
solati et al., 1996; Charafe-Jauffret et al., 2006; Dontu et al., 2003;
Drabsch et al., 2007; Dressman et al., 2001; Gill et al., 2001; Gud-
jonsson et al., 2002; Jones et al., 2004; Kariagina et al., 2007; Liu
et al., 2006; Lu et al., 2008; Monaghan et al., 1995; Parisi et al.,
2008; Perry et al., 2007; Phinney et al., 2005; Rasbridge et al.,
1993; Reis-Filho et al., 2006; Sansone et al., 2007; Shipitsin
et al., 2007; Sleeman et al., 2006; Sørlie et al., 2006) (Table S1
available online). We observed that in both the SUM159 and
SUM149 lines, the expression of genes associated with luminal
differentiationwas indeed enriched in theCD44loCD24hiEpCAMhi
subpopulation (Figures 1C ans 1D and Table S1). For example,
the luminal markers CD24, claudin 1 (CLDN1), and cytokeratins
6B and 8 were all specifically upregulated in CD44loCD24hi
EpCAMhi cells (Figure 1C and Table S1). Similarly, we found
a significant enrichment in the expression of genes associated
with basal differentiation in the CD44hiCD24negEpCAMneg sub-
population (Figures 1C and 1D and Table S1); these genes
included vimentin (VIM), Zeb1 (TCF8), membrane metallo-endo-
peptidase (CALLA/CD10), decorin (DCN), and plasminogen
activator inhibitor type 1 (SERPINE2). Genes implicated in the
self-renewal of embryonic stem cells, including EZH2, KLF5,
KLF4, andSOX9 (Brambrink et al., 2008; Ivanova et al., 2006;Par-634 Cell 146, 633–644, August 19, 2011 ª2011 Elsevier Inc.isi et al., 2008), were significantly enriched in their expression
in the CD44hiCD24negEpCAMlo fraction (Figures 1C and 1D and
Table S1).
The expression levels of genes associated with basal differen-
tiation in the CD44hiCD24negEpCAMneg fraction was further
confirmed via quantitative RT-PCR. Consistent with the microar-
ray data, we observed that CD44hiCD24negEpCAMneg cells from
SUM149 and SUM159 populations expressed elevated levels of
Vimentin, N-cadherin, and Zeb1 compared to unsorted cells
(Figure 1E). In contrast, CD44loCD24hiEpCAMhi cells, which are
in a luminal state, exhibited a reduction in the expression levels
of these basal genes and elevated levels of the luminal epithelial
marker, E-cadherin (Figure 1E). Collectively, these data indi-
cated that, as previously reported, the cell-surface expression
of CD24, CD44, and EpCAM does indeed allow for an accurate
fractionation of cells in distinct differentiation states.
Cell-State Dynamics in Breast Cancer Populations
We next determined the proportions of the individual cell-states
in the SUM159 and SUM149 lines and found that they contained
distinct cell-state proportions: SUM159 populations exhibited
predominantly basal (B) differentiation with minority subpopula-
tions that were stem-like (S) or luminal (L) (proportion of B, S, and
L = 97.3%, 1.9%, and 0.62%, respectively; Figure 2B); in
contrast, SUM149 populations exhibited predominantly luminal
differentiation with stem-like and basal minority subpopulations
(B, S, and L = 3.3%, 3.9%, and 92.8%, respectively; Figure 2B).
Using FACS, we sorted stem-like, basal, or luminal cells from
the SUM159 and SUM149 lines (resulting in subpopulations that
were at least 96% pure based on reanalysis immediately after
sorting). By isolating relatively pure subpopulations of cells in
a given differentiation state and allowing them to expand in
culture, we could monitor how cell-state dynamics evolve over
time (Figure 2A). After 6 days of growth in culture, we assessed
the proportions of stem-like, basal, and luminal cells (Figure 2C).
For each isolated subpopulation, we observed a rapid progres-
sion toward equilibrium proportions (Figure 2C). Two lines of
evidence indicated that this progression was not due to differen-
tial growth rates of cells in the basal, stem-like, or luminal states
but rather to interconversion between states. First, we observed
no difference in the proliferation rates of the stem-like, basal, or
luminal subpopulations sorted from either SUM159 or SUM149
(Figure S1). Second, given the purity of the sorted populations
and the rapid rate of return to equilibrium proportions, some
minority subpopulations would need to divide more than three
times per day to achieve the observed proportions through
differential growth alone. Such a high proliferation rate is implau-
sible because even the most rapidly dividing human cells—
embryonic stem cells—require at least 24 hr to complete a prolif-
eration cycle (Cowan et al., 2004).
Quantitative Markov Model of Cell-State
Interconversion
Given that interconversion between cell states was occurring,
wemodeled these observations as a stochastic process in which
cancer cells transition randomly between states with each pro-
liferative cycle. We additionally made the assumption that
cell transitions follow a Markov process—that is, transition
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Figure 1. Isolation of Stem-like, Luminal,
and Basal Cell-Differentiation States in
Human Breast Cancer Lines
(A) Flow cytometry gating strategy for isolating
CD44loCD24hiEpCAMhi, CD44hiCD24negEpCAMneg,
and CD44hiCD24negEpCAMlo subpopulations from
SUM149 and SUM159 human breast cancer lines.
(B) Morphology of SUM149 and SUM159 colonies
cultured immediately after cell sorting. Repre-
sentative phase-contrast bright-field images of
colonies from sorted CD44lo/CD24hi/EpCAMhi
cells comprised of epithelial islands exhibiting
cobblestone morphology and tight cell-cell junc-
tions, consistent with a luminal cell phenotype.
CD44hi/CD24neg/EpCAMneg cells from colonies
exhibiting spindloid features reminiscent of basal
cell morphology. CD44hi/CD24neg/EpCAMlo colo-
nies are able to exhibit mixed morphologies rep-
resenting luminal and basal phenotypes, consis-
tent with differentiation of stem-like cells.
(C) Messenger RNA (mRNA) was extracted from
the sorted luminal, basal, and stem-like subpop-
ulations and Affymetrix gene chips were then
hybridized to pooled mRNA samples (between
three to five independent sorts were pooled per
marker profile combination and cell line). The heat
map displays differentially expressed genes that
can distinguish between the three cell states.
Genes having multiple instances correspond to
distinct probe sets.
(D) Schematic depicting the results of GSEA per-
formed to determine whether genes previously
published to be associated with luminal, mesen-
chymal or stem cell differentiation are upregulated
in sorted CD44loCD24hiEpCAMhi (luminal),
CD44hiCD24negEpCAMneg (basal), and CD44hi
CD24negEpCAMlo (stem-like) subpopulations. The
ten gene lists analyzed are described in Table S1
and include basal, CD44vsCD24up, TGFb, stem,
differentiated, sphere versus differentiated down,
luminal, luminal A, sphere versus differentiated up,
and mesenchymal. The gene lists are shown su-
perimposed upon the cellular subpopulation(s) in
which they were enriched, together with an
associated p value calculated by permutation
testing. Gene lists with corresponding references
are described in Table S1.
(E) Quantitative RT-PCR analysis of Vimentin,
N-cadherin, E-cadherin, and Zeb1 expression in
SUM149 or SUM159 sorted cell populations
relative to expression in the parental (unsorted)
cell line. Data are represented as the average
DDCt ± standard error of the mean (SEM). n = 3.
See also Table S1.probabilities depend only on a cell’s current state, not on its prior
states (see the Experimental Procedures). Under a Markov
model, it is possible to use data from short-term cell culture ofCell 146, 633–644isolated subpopulations to infer the prob-
abilities of transition between any two cell
states (for example, PB/S denotes the
probability per generation of a basal cell
transitioning into a stem-like state). Byrevealing whether certain transitions are allowed or forbidden,
these inferred probabilities could, in principle, provide significant
insights into the cell-state dynamics in cell lines., August 19, 2011 ª2011 Elsevier Inc. 635
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Figure 2. Determination of Breast Cancer Cell-State Transition Probabilities from Population Cell-State Proportions
(A) Schematic of experimental procedure used to determine cell-state transition dynamics.
(B) Proportions of cell-states in parental SUM159shCntrl and SUM149shCntrl breast cancer lines.
(C) Cellular subpopulations in stem-like (SL), basal, or luminal states were isolated by FACS with antibodies directed against the CD44, CD24, and EpCAM cell-
surface antigens. Bar charts show the proportion of cells in each cell-differentiation state as assessed by FACS after in vitro culture for 6 days.
(D) Lineage hierarchies for the SUM159shCntrl and SUM149shCntrl lines were calculated from the data in (C). The corresponding cell-state transition probabilities for
each cell line are shown. Solid arrows denote transition probabilities greater than 0.1. Dashed arrows denote transition probabilities between 0.01 and 0.1.
See also Figure S1.The transition probabilities for the SUM159 and SUM149 lines
inferred from the experiment above (Figure 2D and Table 1) re-
vealed several interesting similarities and distinctions between
the cell lines:
(1) For both lines, we found that stem-like cells could either
self-renew or transition into either of the basal or luminal
states (Figure 2DandTable1).While the self-renewal prob-
abilitiesarecomparable (PS/S=0.58,0.61), stem-likecells
were more likely to transition into a luminal state in the
SUM149 line (PS/L = 0.30, PS/B = 0.09), but into a basal
state in the SUM159 line (PS/L = 0.07, PS/B = 0.35).
(2) In both cell lines, basal cells exhibited a high probability of
self-renewing divisions (PB/B = 0.99, 0.90). In contrast,
the behavior of luminal cells differed strongly between
the cell lines. Luminal cells in the SUM149 line displayed
a high probability of self-renewal (PL/L = 0.99), while
luminal cells in the SUM159 line exhibited roughly equal
probabilities of either remaining in the luminal state or
transitioning to basal state (PL/L = 0.47; PL/B = 0.49).
These distinctions help explain the higher proportion of636 Cell 146, 633–644, August 19, 2011 ª2011 Elsevier Inc.basal cells observed at equilibrium in the SUM159 line
relative to the SUM149 line.Validation of Markov Model Predictions In Vitro
and In Vivo
The inferred Markov transition probabilities make it possible to
quantitatively predict how a population of cells evolves over
time given the initial proportion of cell states. Examples are
shown in Figure 3 for several initial cell state proportions of
SUM159 populations.
The model makes several unanticipated predictions. First,
even though a subpopulation of sorted stem-like cells from
SUM159 has a low proportion of luminal cells both immediately
after sorting and at 6 days postsort (0.6%), the model predicts
that the proportion of luminal cells will actually show a sharp tran-
sient rise to 7.3% at 1 day postsort (arrow in Figure 3). We
tested this prediction and indeed observed an increase in the
proportion of luminal cells (to 6.5%) at 1 day postsort. This unex-
pected prediction could not have been made without a quantita-
tive model of the underlying cell-state dynamics.
Table 1. Cell-State Transition Probabilities for Control or TBX3-
Inhibited Human Breast Cancer Cells
Control shTBX3
Transition Probabilities S B L S B L
SUM159
Stem 0.58 0.35 0.07 0.50 0.49 0.01
Basal 0.01 0.99 0.00 0.01 0.99 0.00
Luminal 0.04 0.49 0.47 0.06 0.16 0.78
SUM149
Stem 0.61 0.09 0.30 0.63 0.07 0.30
Basal 0.01 0.90 0.08 0.02 0.86 0.12
Luminal 0.01 0.00 0.99 0.01 0.00 0.99
S, B and L correspond to stem-like, basal, and luminal states, respec-
tively. The rows and columns correspond to initial (pretransition) and final
(posttransition) states, respectively. Transition probabilities are shown
per cell division.A second striking prediction of the model is that basal and
luminal cells have a non-zero probability of transitioning to
a stem-like state—that is, that cancer stem-like cells can arise
from non-stem-like cells. This notion stands in stark contrast to
the classical understanding of the concept of ‘‘stem cells’’ in
normal tissues, which posits the existence of a rigid lineage-hier-
archy in which stem cells can give rise to nonstem cells but not
vice versa.
To test this prediction, we evaluated the ability of sorted
SUM159 subpopulations to seed tumors in mice, either after
their initial isolation or after propagation in culture. Consistent
with previous observations, the stem-like fraction could effi-
ciently seed tumors, but neither the luminal nor basal fraction
was capable of doing so (Table 2). The lack of tumor-seeding
potential of luminal and basal subpopulations could be due to
either an inherent inability to give rise to cancer stem cells
(CSCs) in vivo or simply an inability to survive long enough at
the site of implantation to do so. We speculated that admixture
with irradiated carrier cells could allow sorted subpopulations
to survive longer in vivo following injection, as has been previ-Figure 3. Prediction of Cell-State Dynamics with the Stochastic Cell-S
The transition probabilities determined for the SUM159 line were used to compu
stem-like, basal, or luminal cells. For all three isolated subpopulations, an eventu
a transient increase in the proportion of SUM159 luminal cells one day after isolaously shown in the context of hematopoietic reconstitution
(Bonnet et al., 1999).
Accordingly, we coinoculated with GFP-labeled irradiated
parental SUM159 carrier cells. Under these conditions, all three
fractions (stem-like, basal, and luminal) were equally capable of
efficiently seeding tumors (Table 2). In contrast, irradiated
parental SUM159 populations failed to seed tumors on their
own, indicating that irradiation had ablated their tumor-seeding
ability. Examination of the tumors arising from basal and luminal
subpopulations mixed with irradiated carrier cells revealed the
presence of significant numbers of stem-like cells (Table 2).
Moreover, the proportions of basal, stem-like, and luminal cells
in tumors were comparable irrespective of the sorted subpopu-
lation used to seed the tumor (Table 2). Collectively, these results
demonstrated that the luminal and basal fractions can indeed
regenerate functional stem-like cells in vivo and suggested that
convergence toward equilibrium cell-state proportions could
be occurring due to cell-state interconversion within tumors.
The ability of basal and luminal cells to regenerate stem-like
cells de novo is consistent with our finding that basal and luminal
subpopulations return to equilibrium cell-state proportions over
time both in vitro and in vivo. More generally, it is a basic math-
ematical theorem (Perron-Frobenius [Frobenius, 1912; Perron,
1907]) that any finite Markov process satisfying mild conditions
(essentially that there is a path of transitions between any two
states) necessarily returns to a unique stationary distribution
regardless of the starting state. In the context of cancer popula-
tions with nonzero transition probabilities, a Markov process
would cause cellular subpopulations to return to equilibrium
proportions upon propagation.
Influence of Genetic Perturbation on Cell-State
Dynamics
We next examined whether the study of cell-state transition
probabilities could help elucidate how genetic perturbations
affect cell-state dynamics in cancer populations. We studied
the inhibition of the TBX3 gene, which encodes a transcription
factor that is overexpressed in breast cancers (Yarosh et al.,
2008) and regulates differentiation in multiple cell types (Fillmoretate Transition Model
te the expected cell-state proportions over time for isolated subpopulations of
al return to equilibrium cell-state proportions is predicted. The model predicts
tion of a stem-like subpopulation (red arrow).
Cell 146, 633–644, August 19, 2011 ª2011 Elsevier Inc. 637
Table 2. Incidence and Phenotype Analyses of Tumors Arising from Sorted SUM159 Subpopulations
SUM159 Subpopulations Analysis of Formed Tumors
Basal Stem-like Luminal Tumor Incidence Viable cells (%) GFP-neg H2K-neg (%) Basal (%) Stem-like (%) Luminal (%)
Direct Injection
+ – – 0/4
– + – 4/4 17.11 49.34 93.38 6.03 0.59
– – + 0/4
With GFP + Irrad. SUM159
– – – 0/4
+ – – 4/5 58.1 ± 2.1 56.0 ± 6.0 81.7 ± 5.9 11.4 ± 3.5 6.9 ± 2.4
– + – 4/5 53.4 ± 4.7 56.7 ± 7.7 67.2 ± 11.4 24.1 ± 8.0 8.6 ± 3.5
– – + 4/5 65.7 ± 6.3 57.7 ± 7.2 82.4 ± 8.1 12.0 ± 6.5 5.6 ± 2.7
Sorted SUM159 CD44loCD24hiEpCAMhi (luminal) CD44hiCD24negEpCAMneg (basal), and CD44hiCD24negEpCAMlo (stem-like) subpopulations (104 per
injection) were either directly implanted into NOD/SCID mice alone (direct injection) or coinoculated with 106 GFP-labeled irradiated SUM159 parental
carrier cells prior to implantation in vivo. The fraction of viable cells after tumor dissociation was assessed by propidium iodide staining coupled with
flow-cytometry analysis. H2K and GFP were used to exclude contamination of mouse and GFP-positive carrier cells. Luminal, basal, and stem-like
proportions within the viable cancer cells of the resulting SUM159 tumors are shown.et al., 2010; Govoni et al., 2009; Howard and Ashworth, 2006;
Ivanova et al., 2006; Lee et al., 2007). To inhibit TBX3 function,
we developed and validated short hairpin RNA (shRNA)
constructs targeting the TBX3 gene. We then isolated stem-
like, basal, or luminal subpopulations from SUM149 and
SUM159 cells in which TBX3 expression had been inhibited.
After 6 days in culture, we determined the cell-state proportions
in TBX3-inhibited populations and computed the corresponding
transition probabilities (Table 1).
The results reveal that in SUM159 cells, TBX3 inhibition
decreased the probability of luminal-to-basal cell state transitions
and increased the likelihood of self-renewing divisions for the
luminal state (PL/B decreases from 0.49 to 0.16, while PL/L
increases from0.47 to 0.78; Table 1). InSUM149cells, onecannot
measure whether TBX3 inhibition causes a decrease in PL/B or
an increase in PL/L, because the former is 0.00 and the latter is
0.99 in the absence of inhibition. However, TBX3 inhibition in the
SUM149 line resulted in an increase in the probability of basal-
to-luminal transitions (PB/L increases from 0.08 to 0.12; Table 1).
These findings indicated that TBX3promotes basal differentiation
by distinct mechanisms, depending on the underlying cell-state
transitions present in a given cancer cell population.
Inferring Cell-State Treatment Sensitivities
with a Markov Model
Cell-state dynamics can also be applied to study the differential
toxicities of collections of potential anticancer drugs on various
cell states. Such studies are of particular importance because
of the observed resistance of cancer stem-like cells to chemo-
and radiation therapies (Bao et al., 2006; Dean et al., 2005; Diehn
and Clarke, 2006; Eyler and Rich, 2008; Li et al., 2008; Wood-
ward et al., 2007). This has fueled interest in identifying drugs
that selectively target specific cell-differentiation states. One
approach to finding such drugs would be to use high-throughput
flow cytometry to screen collections of chemicals for their effects
on cell-state proportions.
To explore this idea, we treated SUM159 and SUM149 cells
with two commonly used breast cancer chemotherapy drugs:638 Cell 146, 633–644, August 19, 2011 ª2011 Elsevier Inc.paclitaxel and 5-fluorouracil (5-FU) (Figure 4A). For both cell lines,
we observed that treatment with either drug resulted in an
increase in the relative proportion of stem-like cells (each drug
was applied at a concentration that resulted in 90% inhibition of
viability). In SUM159 cells, treatment with either paclitaxel or (to
a lesser degree) 5-FU also increased the proportion of cells in
a luminal state. In contrast, treatment of SUM149 cells with either
paclitaxel or 5-FU resulted in expansion of cells in the basal state.
To understand these observations, we expanded our model to
allow the three cell states to have different relative viabilities in
response todrug treatment.Weused thesame transitionprobabil-
ities as previously determined for each cell line, but incorporated
drug treatment effects by pre-multiplying the transition matrix by
adiagonalmatrixof relativeviabilities (vB, vS, vL). The relativeviabil-
ities represent the survival probability per generation for each cell
state,with the valuesnormalized to sum to1.Because they sum to
1, the values can be represented as points in a ternary plot (that is,
an equilateral triangle in which the three coordinates are repre-
sented by the distance to each side). We then used Monte Carlo
simulation to infer the relative viability matrix most consistent
with the cell-state proportions observed following drug treatment.
Results of this analysis are shown in the ternary density plots in
Figure 4C,with the color of eachpoint representing the normalized
difference between the experimentally observed and predicted
cell-state proportions. The viability values most consistent with
the data are shown as a dark brown region in Figure 4C.
For the SUM159 line, the viability parameters were con-
strained to a small region and imply that basal cells were more
sensitive than the other cell-states to paclitaxel treatment (values
tightly centered around vB = 0.1 ± 0.025, vS = 0.4 ± 0.05, vL = 0.5
± 0.05) (Figure 4C). In contrast, the differential viabilities were not
well constrained for 5-FU treatment. For SUM149 cells, the
viabilities were tightly constrained and approximately equal for
both drugs (vB = 0.15 ± 0.15, vS = 0.68 ± 0.12, vL = 0.22 ±
0.05), and indicate that the stem-like cells were selectively resis-
tant to treatment (Figure 4C).
These results provide insight into the observation that pacli-
taxel treatment of SUM149 cells leads to an 5-fold increase
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Figure 4. Analysis of Chemical Treatment Sensitivities by Monte Carlo Simulation with the Stochastic Cell-State Transition Model
(A) Cell-state proportions after a 6 day treatment with either paclitaxel or 5-FU are shown for SUM159 and SUM149 populations.
(B) A schematic showing how differential chemical treatment sensitivities can be incorporated into the Markov stochastic model. The matrix of transition
probabilities is premultiplied by a differential viability matrix. The diagonal entries of thismatrix, (vB, vS, and vL), encode the survival probabilities of basal, stem-like
and luminal cells in the presence of chemical treatment. These entries are normalized to sum to 1. Monte Carlo simulation is performed by random sampling of
differential viability vectors.
(C) The results of Monte Carlo simulation, shown as ternary density contour plots in which coloration represents the normalized difference (see the Experimental
Procedures for the metric used) between experimentally observed and predicted cell-state proportions following chemical treatment. Ten thousand random
points within the triangle simplex were sampled, each representing a distinct choice of differential viability vector, (vB, vS, vL), with entries ranging from zero
(sensitive) to one (resistant).in both stem-like and basal cells. In particular, they reveal that
the relative increase in the proportion of basal cells does not
reflect a selective resistance of basal cells to paclitaxel treat-
ment. Rather, it is an indirect effect arising from the selective
resistance of stem-like cells, which then expand and give rise
to basal cells. This important inference would not have been
possible without taking into account the lineage-structure (i.e.,
cell-state transition probabilities) of the SUM149 line.
DISCUSSION
While malignant transformation is invariably associated with the
perturbation of normal regulatory mechanisms, one of thepuzzling features of cancer cell populations is their ability to retain
phenotypic equilibrium over extended periods of time. Popula-
tions of cancer cells, for example, often harbor subpopulations
with specific cell-surface marker profiles that are stably main-
tained across many cell divisions in culture. The observations
here demonstrate that such equilibrium is maintained through
the interconversionof cancercellsbetweenstates, the latter being
defined based on cell-surface marker expression. We have
described a Markov model of cell-state dynamics that assumes
interconversation rates depend only on a cell’s current state and
remain constant under fixed microenvironmental conditions.
A specific prediction of this quantitative model is that any
subpopulation of cancer cells will return to a fixed equilibriumCell 146, 633–644, August 19, 2011 ª2011 Elsevier Inc. 639
of cell-state proportions over time, provided that it is possible
through one or more interconversions to transition between
any two states. The cell-state proportions at this equilibrium
can be derived from the transition rates as the second eigen-
vector of the corresponding transition probability matrix. One
corollary of this prediction is that deviations from equilibrium
proportions will be corrected even in the absence of any intercel-
lular communication. Therefore, while intercellular signals clearly
influence cell-state decisions, they are not necessarily required
for stability in phenotypic proportions. Thus, for many types of
cancer populations, it is possible that phenotypic equilibrium is
maintained in culture in the absence of regulatory feedback
mechanisms.
The prediction that cell-state proportions in any subpopulation
would return to a stable equilibrium does not depend on the
strong form of the Markov property assumed above—namely,
that cells lack any memory of their prior states. A more modest
form of the Markov condition—that cell-state decisions depend
only a fixed depth of prior history—would also be sufficient to
promote a stable phenotypic equilibrium, provided there is
weak interconnectedness between states as described above.
The prediction of a return to phenotypic equilibrium is consis-
tent with the finding that CSCs give rise to tumors that recapitu-
late the differentiation-state heterogeneity present in the
parental tumors fromwhich they were derived. Our observations
with breast cancer lines in vitro indicate that cells in CSC-
depleted fractions give rise to cells expressing marker profiles
that enrich for CSCs (Chaffer et al., 2011). If a similar interconver-
sion occurs after in vivo injection, a prediction of themodel would
be that CSC-depleted fractions would give rise to tumors if they
survived long enough at the site of implantation to regenerate
CSCs. In support of this idea, we found that coimplantation
with irradiated carrier cells enabled the luminal, basal and stem-
like fractions of the SUM159 breast cancer line to form tumors
with high efficiency. Additionally, as predicted by the Markov
model, similar cell-state proportions were observed in tumors
generated by the luminal, basal and stem-like fractions and in
tumors generated from unfractionated populations. While these
observations are consistent with the Markov model proposed
here, further experimentation will be needed to quantify the rates
of interconversion between cancer cell states in vivo.
The experiments described here used sorted subpopulations
with relatively large numbers of cells. Accordingly, the transition
rates determined represent population averages over numerous
cancer cells. Therefore, it is possible that interconversion rates
might vary significantly across the individual cancer cells of
any particular sorted subpopulation. To determine whether
such variability exists, further experimentation will be needed
to quantify interconversation rates among the progeny of
single-cell clones. For such an experiment, cancer-cell clones
would need to be grown under conditions that control for effects
on interconversion rates arising from sparsity in culture. Such
variability, if observed, could arise from two sources: (1) the
cell-surface markers failed to segregate epigenetically uniform
subpopulations or (2) there are genetic differences among
cancer cells that are in identical epigenetic states.
If observed, variability in interconversion rates across indi-
vidual cells would not alter the predictive value, at a population640 Cell 146, 633–644, August 19, 2011 ª2011 Elsevier Inc.level, of the Markov model proposed here. Indeed, the ability of
theMarkovmodel to predict the dynamics of cell-surfacemarker
profiles does not depend on a one-to-one correspondence
between biological states and the cell-surface marker profiles
used to segregate subpopulations. Moreover, a subsequent
refinement of the markers allowing for the discrimination of addi-
tional states would lead to a natural extension of the model.
In adult tissues, specialized niche cells supply stem and
progenitor cells with paracrine signals necessary for their main-
tenance or expansion. In contrast, due to their acquired genetic
lesions, cancer cells can stochastically enter into stem-like
states in the absence of normal niche microenvironments. For
example, RB loss in animal models of osteosarcoma can cause
dedifferentiation of bone-committed progenitors, resulting in
cancer cell plasticity and the ability to generate tumors of
multiple lineages (Calo et al., 2010; Gutierrez et al., 2008). As
another example, mutations in the BRCA1 gene inhibit the ability
of breast cancer cells to differentiate into the luminal lineage,
resulting in less-differentiated tumors.
While our study was limited to mutated cancer cell popula-
tions, there is evidence indicating that ostensibly normal cells
that are differentiated can either transdifferentiate or transition
into more primitive states. Such differentiation-state plasticity
occurs in response to either genetic or microenvironmental per-
turbations (Deng et al., 2011; Thorel et al., 2010; Zhou et al.,
2008) and has also been observed during normal developmental
processes (Richard et al., 2011). It will be of significant interest to
determine how adult cells acquire plasticity, since modulation of
the underlying mechanisms could lead to novel therapies for
regenerative medicine.
While our findings indicate that cancer stem-like cells can arise
de novo from non-stem-like cells at a low but significant rate, it is
unclear whether the presence of such plasticity indicates that the
concept of cancer stem cells is fundamentally different from that
of normal stem cells. Indeed, the plasticity described above
suggests that the lineage-hierarchy associated with normal cells
may be more flexible than is commonly depicted (Figure 5,
model I versus II).
The de novo generation of CSCs has implications for the effec-
tiveness of anticancer therapies that exclusively target CSCs,
because non-CSCs would regenerate CSCs after cessation of
therapy and lead to renewed tumor growth. Therefore, in order
to be effective, cancer therapies will need to combine agents
that are selectively toxic to CSCs with agents that either target
the bulk non-CSC populations within tumors or inhibit transitions
from non-CSC to CSC states.
The Markov model described here allows for the quantitative
inference of transition probabilities between phenotypic states
within cancer cell populations. The marker profiles studied
here correlate with particular differentiation states associated
with mammary epithelial cells. However, the model described
here could be applied to subpopulations isolated using any other
cell-surface marker profiles. In principle, themodel could also be
extended to other biological settings in which stochastic state
transitions occur, either in normal or diseased contexts. In
such applications, it is possible that proliferation or survival rates
could differ across cell-states. If this is the case, additional mea-
surements quantifying the viability differences or model-fitting
Figure 5. Two Distinct Models of Cancer
Cell Populations
In the existing paradigm (model I), CSCs give rise
to non-CSCs but not vice versa, resulting in
a hierarchical cell-lineage structure reflective of
normal tissue biology. We propose an alternative
scenario (model II) in which there is bidirectional
interconversion between CSC and non-CSC
states. The rates of transition between cell states,
which vary across distinct cancer cell populations,
can be computed with the Markov modeling
approach described in the main text and Experi-
mental Procedures.approaches would be needed in order to extend the model
described here.
Interconversion of cells between differentiation states compli-
cates the interpretation of experiments in which cell-state
proportions aremeasured in populations of cells following chem-
ical or genetic perturbation. Our findings indicate that knowledge
of inter-conversion rates is needed to accurately characterize
the effects of perturbations on cell-state dynamics. The model
proposed makes it possible to systematically characterize how
cell-state transitions are influenced by experimental perturba-
tions. In addition to being practically useful, the ability to relate
cell-state transition probabilities at the single-cell level to the
dynamics of population cell-state proportions should prove
useful in future theoretical studies of phenotypic complexity.EXPERIMENTAL PROCEDURES
Description of the Cell-State Transition Markov Model
The Markov model makes several assumptions: (1) cells within a population
can exist in any one ofM possible states and (2) under fixed genetic and envi-
ronmental conditions, cells transition from one state to another with transition
rates per unit time that are constant.
Let Pij denote the probability that a cell transitions from state i to state j.
Since a given cell must either remain in the same state or enter into one of
the other possible M-1 states, it follows that for all i,
XM
j =1
Pij =1:Cell 146, 633–644A population of cells can be described by
a single row-vector v of dimension k in which the
ith entry of the vector is the proportion of cells
that are present in the ith phenotypic state. Since
all cells must exist in one of the k states, it follows
that for any n,
XM
i = 1
ni = 1:
Given these assumptions, the dynamic evolu-
tion over time of the various cell state proportions
is a Markov process. The rates of transition
between states can be encoded in a (M 3 M)
stochastic matrix P with row-sums equal to 1
that encodes the transition rates per unit time.
Given a vector encoding the initial cell-stateproportions at time 0, v(0), and the stochastic matrix P, it is possible to calcu-
late cell-state proportions after T time units:
nðTÞ = nð0Þ,

PT

:
Computation of the Stochastic Matrix Associated with a Population
of Cells
To predict the evolution of phenotypic proportions in a cellular population, the
transition probabilities and initial state vector for the population need to be
determined. The initial state vector corresponds to the proportions of the
various cell states at time 0. To compute the matrix of transition probabilities,
P, it is necessary to observe the evolution of at leastM populations for a fixed
length of time, T. Any set of M populations would suffice to determine P,
provided that the initial state vectors corresponding to the distinct populations
span RM. This information is sufficient to determine the stochastic matrix in
cases where proliferation and survival rates do not differ between states.
For example, one could use as starting populations theM distinct subpop-
ulations for which all cells in a population are present in one of the states S1,
S2,., SM. The observed state-vector at time T for population Si is given by
the ith row of the matrix P (T) where P represents the transition rates per unit
time. Accordingly, the matrix P would equal the matrix of observations raised
to the power (1/T).
Monte Carlo Simulation with Transition Probabilities for Analysis
of Treatment Sensitivity
We assumed that compound treatment affects cell viability but not the cell-
state transition probabilities for a given population. The differential treatment
sensitivities for the k distinct cell states were represented in a diagonal (M 3
M) matrix with diagonal elements encoding survival probabilities summing to
one. Together, the differential treatment sensitivity and transition probabilities
allow for in silico predictions of cell state proportions after treatment. To, August 19, 2011 ª2011 Elsevier Inc. 641
determine the differential drug sensitivities that best correspond to experi-
mental observations following treatment, Monte Carlo simulation was per-
formed by randomly sampling treatment sensitivity vectors from the (M-1)-
simplex. The initial cell-state proportions prior to treatment were assumed to
be at equilibrium. For each cell line, the predicted cell-state proportions after
6 days of treatment were determined from the differential treatment sensitivity
matrix and the matrix of transition probabilities for the cell line. The normalized
distance,D, between the observed n io b s and predicted n
i
p r e d cell-state propor-
tions was calculated with the metric
D=
XM
i =1
jn io b s  n ip r e d j
n ie q
;
where n ie q are the equilibrium proportions.
Cell Lines and Tissue Culture
SUM cell lines were obtained from Stephen Ethier (Karmanos Institute, MI) and
are commercially available (Asterand); SUM149 and SUM159 cells were
cultured in Ham’s F12 medium with 5% calf serum, insulin (5 mg/ml), and
hydrocortisone (1 mg/ml). All cell lines were grown at 37C in a 5% CO2
incubator.
Microarray Hybridization and Global Gene Expression Profiling
Total RNA for gene-expression studies was isolated from sorted stem-like
(CD44hiCD24negEpCAMlo), basal (CD44hiCD24negEpCAMneg), and luminal
(CD44loCD24hiEpCAMhi) subpopulations from SUM149 and SUM159 cell
cultures with the RNeasy Mini kit (QIAGEN). Synthesis of complementary
DNA from total RNA and hybridization/scanning of microarrays were per-
formed with Affymetrix GeneChip products (HGU133A) as described in the
GeneChip manual. Raw data files (.CEL) were converted into probe-set values
by RMA normalization using the affy package in R (Gentleman et al., 2004).
After RMA normalization, the limma R package (Smyth, 2004) was used to
determine regression coefficients, identifying probes differentially expressed
between stem versus basal cells, stem versus luminal and luminal versus basal
cells for the SUM149 and SUM159 lines. Hierarchical clustering was per-
formed with the Pearson correlation metric, using probes consistently regu-
lated across both lines. GSEAwas performed as described previously (Mootha
et al., 2003; Subramanian et al., 2005), using gene lists previously reported to
characterize stem, luminal, and basal cells (Table S1). GSEAwas on performed
for each pair-wise comparison on probe lists preranked based on the sum of
the regression coefficients for both lines. Probe sets were collapsed to gene
scores based on maximal intensity.
Lentiviral Infection of shRNA Constructs
Bacterial glycerol stocks of MISSION shRNAs were obtained (SIGMA) and
plasmid DNA was isolated by mini-prep (QIAGEN). pLKO.1 (0.6 mg) plasmid
containing the shRNA constructs targeting Tbx3 or no known target (Scram-
bled) were transiently cotransfected into S293T cells along with the VSV-G-
expressing construct pCMV-VSV-G and the packaging construct pCMV
DR8.2Dvpr generously provided by Inder Verma (Salk Institute). Viral superna-
tant was collected and introduced to subconfluent SUM149 or SUM159
cultures. Lentiviral integration was selected with 1 mg/ml puromycin for
7 days, and knockdown efficiency was measured by quantitative RT-PCR.
The Tbx3 clone ID is NM_016569.2-443s1c1 50ATTGATCCATGATC
GGCTTGG30.
Fluorescence-Activated Cell Sorting
Subconfluent cultures were trypsinized, counted, washed with PBS, and
stained with antibodies specific for the following human cell-surface markers:
EpCAM (ESA)-FITC (clone VU-ID9, AbD Serotec), CD24-PE (clone ML5, BD
PharMingen), and CD44-APC (clone G44-26, BD PharMingen). For each stain-
ing reaction, cells were incubated with antibody (20 ml antibody per million
cells) for 15 min at room temperature. Unbound antibody was washed off,
and cells were analyzed on a BD FACSCaliber no more than 1 hr after staining.
Isotype controls included mouse IgG1-FITC, mouse IgG2ak-PE, and mouse642 Cell 146, 633–644, August 19, 2011 ª2011 Elsevier Inc.IgG2bk-APC (BD PharMingen). Cell sorting for subsequent culture was per-
formed on a MoFlo cell sorter (Cytomation).Tumor formation Experiments
All animal procedures were conducted in accordance with a protocol
approved by the Tufts University IACUC committee. Nulliparous NOD/SCID
female mice aged 6–8 weeks were used for all injection experiments. Human
breast cancer cells were suspended in 30 ml phosphate-buffered saline and in-
jected into the fourth inguinal mammary glands of mice. Tumor formation was
assessed by palpitation. Tumors were dissociated with Collagenase Type IV
and 0.25% Trypsin (Invitrogen). Viable human cells were isolated from disso-
ciated tumors by negative selection of GFP-positive irradiated carrier cells,
propidium iodide-positive cells, and mouse pan H2K-MHCI-PE-positive cells.
The FACS-sorted viable human cells were then stained for flow cytometry as
described above for cell lines.SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and one table and can be found
with this article online at doi:10.1016/j.cell.2011.07.026.ACKNOWLEDGMENTS
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